Total Raised

$57.7M

Investors Count

14

Deal Terms

1

Ultromics Funding, Ultromics Valuation & Ultromics Revenue

6 Fundings

Ultromics's latest funding round was a Series B for $33M on August 16, 2021.

Ultromics's valuation in May 2018 was $47.07M.

Date

Round

Amount

Investors

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Revenue

Sources

8/16/2021

Series B

$33M

0

FY undefined

23

6/16/2020

Series A - III

$99M

0

FY undefined

10

10/8/2018

Series A - II

$99M

0

FY undefined

10

5/22/2018

Series A

$99M

$47.07M

0

FY undefined

10

7/15/2017

Seed VC

0

FY undefined

10

Date

8/16/2021

6/16/2020

10/8/2018

5/22/2018

7/15/2017

Round

Series B

Series A - III

Series A - II

Series A

Seed VC

Amount

$33M

$99M

$99M

$99M

Investors

Valuation

$47.07M

Revenue

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

0

FY undefined

Sources

23

10

10

10

10

Ultromics Deal Terms

1 Deal Term

Ultromics's deal structure is available for 1 funding round, including their Series A from May 22, 2018.

Round

Series A

Funding Date

$99M

Pre-Money Valuation

Post-Money Valuation

Amount Raised

$99M

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

$99M

Board Voting

$99M

Par Value

Round

Funding Date

Pre-Money Valuation

Post-Money Valuation

Amount Raised

Shares Authorized

Issuance Price

Dividend Rate

Liquidation Preferences

Liquidation Price

Participation

Conversion Price

Anti Dilution

General Voting

Board Voting

Par Value

Series A

$99M

$99M

$99M

$99M

Ultromics Investors

14 Investors

Ultromics has 14 investors. Oxford Sciences Innovation invested in Ultromics's Series B funding round.

First funding

Last Funding

Investor

Rounds

Board Seats

Type

Location

7/15/2017

8/16/2021

4
Seed VC, Series A (2018), Series A - III (2020), Series B (2021)

Venture Capital

United Kingdom

8/16/2021

8/16/2021

1
Series B

Corporate Venture

California

8/16/2021

8/16/2021

1
Series B

Corporate Venture

Illinois

00/00/0000

00/00/0000

Optum Ventures

Subscribe to see more

Corporate Venture

California

00/00/0000

00/00/0000

Mayo Clinic

Subscribe to see more

Non-Profit Foundation

Minnesota

First funding

7/15/2017

8/16/2021

8/16/2021

00/00/0000

00/00/0000

Last Funding

8/16/2021

8/16/2021

8/16/2021

00/00/0000

00/00/0000

Investor

Optum Ventures

Mayo Clinic

Rounds

4
Seed VC, Series A (2018), Series A - III (2020), Series B (2021)
1
Series B
1
Series B

Subscribe to see more

Subscribe to see more

Board Seats

Type

Venture Capital

Corporate Venture

Corporate Venture

Corporate Venture

Non-Profit Foundation

Location

United Kingdom

California

Illinois

California

Minnesota

You May Also Like

A
Aidoc Medical

Aidoc finds and flags critical findings in medical images. By automatically prioritizing urgent, life-threatening conditions like intracranial hemorrhage and pulmonary embolism, Aidoc saves lives, improves patient care and cuts waiting time for the must urgent patients down to only a few minutes. The always-on AI integrates into a radiologist's workflow, reprioritizing cases without forcing radiologists to change the way they work. Aidoc was founded in 2016 and is based in Tel Aviv, Israel.

Infervision Logo
Infervision

Infervision is a global high-tech enterprise in medical artificial intelligence, aiming to empower doctors with higher efficiency and benefit patients with better diagnosis, outcome, and lower cost. Infervision provides products and services to providers, and patients; with robust A.I. solutions fully integrated with the healthcare workflow to help diagnosing various diseases and conditions such as cerebral hemorrhage, lung cancer, bone fractures, emphysema, and more. Infervision also provides an AI-powered research platform for medical professionals with any research directions and needs.

Koios Medical Logo
Koios Medical

Koios Medical is a provider of software solutions for radiologists diagnosing cancer. Using AI algorithms trained on thousands of images combined with data from pathology results, Koios DS™ is decision support for healthcare diagnostics.

QUIBIM Logo
QUIBIM

Quibim, a company with its headquarters in Valencia, Spain, provides a whole-body medical imaging analysis. Quibim products are used worldwide by a huge diversity of research and care teams. Partners use Quibim Precision, a CE-marked whole-body imaging ecosystem, for a wide range of applications from detecting a disease to tracking the efficacy of treatments. Quibim follows an AI-first approach to help detect pathologies across every body part and imaging modality, using quantitative imaging biomarkers.

Viz.ai Logo
Viz.ai

Viz.ai aims to use artificial intelligence and deep learning to automatically identify suspected LVOs (large vessel occlusion) on CTA imaging with the aim of alerting a patient's physician within minutes. The company was founded in 2016 and is based in San Francisco, California.

S
Shukun Technology

Shukun Technology develops diagnostic systems by using machine learning and AI technology for hospitals to improve efficiency. The company focuses on cardiovascular diagnosis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.